Clinical Trial
Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation
Affiliations
- PMID: 15026517
- PMCID: PMC1738998
Item in Clipboard
Clinical Trial
Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation
J Neurol Neurosurg Psychiatry.
2004 Apr.
Abstract
To assess whether brain tissue loss occurs after profound and sustained suppression of magnetic resonance imaging (MRI) enhancement, we measured brain volume changes from 10 patients with rapidly evolving secondary progressive multiple sclerosis (MS) treated with autologous haematopoietic stem cell transplantation and followed up for 24 months. An average yearly decrease of brain volume of about 1.9% was observed despite only five enhancing lesions seen on triple dose follow up scans of two patients. This indicates that, in MS, progressive loss of tissue can occur independently of concomitant MRI-visible inflammation.
Similar articles
-
A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.AJNR Am J Neuroradiol. 2007 Oct;28(9):1659-61. doi: 10.3174/ajnr.A0644. Epub 2007 Sep 20. AJNR Am J Neuroradiol. 2007. PMID: 17885242 Free PMC article. Clinical Trial.
-
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.Vojnosanit Pregl. 2016 May;73(5):504-8. doi: 10.2298/vsp150304045o. Vojnosanit Pregl. 2016. PMID: 27430119
-
Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.AJNR Am J Neuroradiol. 2003 Apr;24(4):658-62. AJNR Am J Neuroradiol. 2003. PMID: 12695199 Free PMC article. Clinical Trial.
-
Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature.J Neuroimaging. 2002 Oct;12(4):302-9. doi: 10.1111/j.1552-6569.2002.tb00137.x. J Neuroimaging. 2002. PMID: 12380476 Review.
-
Autologous haematopoietic-stem-cell transplantation for multiple sclerosis.Lancet Neurol. 2005 Jan;4(1):54-63. doi: 10.1016/S1474-4422(04)00966-4. Lancet Neurol. 2005. PMID: 15620857 Review.
Cited by
-
A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis.AJNR Am J Neuroradiol. 2007 Oct;28(9):1659-61. doi: 10.3174/ajnr.A0644. Epub 2007 Sep 20. AJNR Am J Neuroradiol. 2007. PMID: 17885242 Free PMC article. Clinical Trial.
-
Emerging therapies for multiple sclerosis.Neurotherapeutics. 2007 Oct;4(4):676-92. doi: 10.1016/j.nurt.2007.07.003. Neurotherapeutics. 2007. PMID: 17920549 Free PMC article. Review.
-
Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis.J Neurol. 2005 Nov;252 Suppl 5:v10-5. doi: 10.1007/s00415-005-5003-6. J Neurol. 2005. PMID: 16254696 Review.
-
MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.J Neurol. 2005 Nov;252 Suppl 5:v16-24. doi: 10.1007/s00415-005-5004-5. J Neurol. 2005. PMID: 16254697 Review.
-
Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.J Neurochem. 2006 Sep;98(6):1817-27. doi: 10.1111/j.1471-4159.2006.04081.x. Epub 2006 Aug 3. J Neurochem. 2006. PMID: 16899071 Free PMC article.
